Skip to content
Technology
About us
Pipeline
News
Careers
Menu
Technology
About us
Pipeline
News
Careers
CONTACT
Uncategorized
November 1, 2024
Prokarium expands IP portfolio with two new U.S. patents strengthening its position in bladder cancer
LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...
Read more
November 1, 2024
Prokarium expands IP portfolio with two new U.S. patents strengthening its position in bladder cancer
LONDON, United Kingdom, November 1, 2024 – Prokarium, a biopharmaceutical company developing innovative cancer treatments, today announced the...
Read more
March 14, 2024
Prokarium Secures UKRI Grant to Fund Development of Living Cures Platform
LONDON, UK, March 14, 2024 – Prokarium announces they have been awarded a UK Research and Innovation (UKRI) Engineering Biology...
Read more
March 14, 2024
Prokarium Secures UKRI Grant to Fund Development of Living Cures Platform
LONDON, UK, March 14, 2024 – Prokarium announces they have been awarded a UK Research and Innovation (UKRI) Engineering Biology...
Read more
February 7, 2024
Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial
London, UK – February 7, 2024 – Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic...
Read more
February 7, 2024
Prokarium Achieves Milestone with First Patient Dosing in PARADIGM-1 Non-Muscle Invasive Bladder Cancer Clinical Trial
London, UK – February 7, 2024 – Prokarium, a clinical-stage biopharmaceutical company bioengineering Living Cures through cutting-edge synthetic...
Read more
November 2, 2023
Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program
London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...
Read more
November 2, 2023
Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program
London, UK – November 2, 2023 – Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create...
Read more
February 9, 2023
Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform
London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...
Read more
February 9, 2023
Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform
London, UK February 9, 2023 – Prokarium, a biopharmaceutical company leading the oncology field of microbial immunotherapy, has...
Read more
January 9, 2023
Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology
LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...
Read more
January 9, 2023
Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology
LONDON, UK and BOSTON, MA — January 9, 2023 — Prokarium, a biopharmaceuticalcompany pioneering the oncology field of...
Read more
October 19, 2022
Prokarium Strengthens Manufacturing Capabilities with Appointment of Peter Juul Madsen as Vice President of CMC
LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
Read more
October 19, 2022
Prokarium Strengthens Manufacturing Capabilities with Appointment of Peter Juul Madsen as Vice President of CMC
LONDON, UK – October 19, 2022 – Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy,...
Read more
October 5, 2022
Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies
LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the ‘Company’), a biopharmaceutical company pioneering the...
Read more
October 5, 2022
Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Combination with Cell Therapies
LONDON, United Kingdom, October 5, 2022 – Prokarium Ltd (‘Prokarium’ or the ‘Company’), a biopharmaceutical company pioneering the...
Read more
Icons
Technology
About us
Pipeline
News
Careers
Technology
About us
Pipeline
News
Careers
CONTACT